Daily Archives: November 27, 2018

Medibio Signs Insurance Company AIA Australia Ltd (AIAA) For an Exclusive Pilot Program For ilumen™

SYDNEY, Australia and MINNEAPOLIS, Nov. 27, 2018 (GLOBE NEWSWIRE) — Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), a mental health technology company announces that it has signed an exclusive agreement with AIAA to undertake a pilot program for the latest release of its corporate health program, ilumen™.

AIAA is one of Australia’s leading life insurers, offering a range of products that protect the financial health and wellbeing of more than 4 million Australians.  AIAA is part of the AIA Group, the largest independent publicly listed pan-Asian life insurance group – with a presence in 18 markets around the Asia-Pacific region.

AIAA will have access to ilumen™ over a six-month period for its Australia and New Zealand employees.

A unique solution for corporate health programs seeking to offer support for mental wellness, ilumen provides participants with a two-part system for checking and monitoring symptoms of depression, anxiety, and stress. Coupling Medibio’s key biometric data and a subjective assessment, users get a ‘wellness snapshot’ that they can track and make improvements to over time.

Senior Vice President of Corporate Health at Medibio, Jennifer Solitario says “AIAA provides a great opportunity for ilumen™. Our objective is to bring our unique mental health technology to as many people as possible. AIAA offers us an opportunity to partner with a leading organisation with a genuine interest in helping to support mental health for its people.”

Damien Mu, AIA Australia & New Zealand CEO, says “AIAA recognises the crucial role mental health plays in an individual’s overall health. We will continue to explore ways of improving the support that we provide to our staff, customers and partners as we strive to help people live healthier, longer, better lives.”

About Medibio Limited
Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective digital biomarkers to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices located in Melbourne (Vic), Perth (WA) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

Further Information:  Website: www.medibio.com.au
Medibio Enquiries:
Kristi Hamilton
Senior Marketing Communication Manager
Medibio Limited
kristi.hamilton@medibio.com.au
T: +1 952 232 0934
Investor Enquiries:
Peter Taylor
NWR Communications
peter@nwrcommunications.com.au
T: +61 (0) 412 036 231

Cisco Predicts More IP Traffic in the Next Five Years Than in the History of the Internet

SAN JOSE, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) — The internet is made up of thousands of public and private networks around the world. And since it came to life in 1984, more than 4.7 zettabytes of IP traffic have flowed across it. That’s the same as all the movies ever made crossing global IP networks in less than a minute.

Yet the new Visual Networking Index (VNI) by Cisco predicts that is just the beginning. By 2022, more IP traffic will cross global networks than in all prior ‘internet years’ combined up to the end of 2016. In other words, more traffic will be created in 2022 than in the 32 years since the internet started. Where will that traffic come from? All of us, our machines and the way we use the internet. By 2022, 60 percent of the global population will be internet users. More than 28 billion devices and connections will be online. And video will make up 82 percent of all IP traffic.

“The size and complexity of the internet continues to grow in ways that many could not have imagined. Since we first started the VNI Forecast in 2005, traffic has increased 56-fold, amassing a 36 percent CAGR with more people, devices and applications accessing IP networks,” said Jonathan Davidson, senior vice president and general manager, Service Provider Business, Cisco. “Global service providers are focused on transforming their networks to better manage and route traffic, while delivering premium experiences. Our ongoing research helps us gain and share valuable insights into technology and architectural transitions our customers must make to succeed.”

Key predictions for 2022

Cisco’s VNI looks at the impact that users, devices and other trends will have on global IP networks over a five-year period. From 2017 to 2022, Cisco predicts:

  1. Global IP traffic will more than triple

    • Global IP traffic is expected to reach 396 exabytes per month by 2022, up from 122 exabytes per month in 2017. That’s 4.8 zettabytes of traffic per year by 2022.
    • By 2022, the busiest hour of internet traffic will be six times more active than the average. Busy hour internet traffic will grow by nearly five times (37 percent CAGR) from 2017 to 2022, reaching 7.2 petabytes1 per second by 2022. In comparison, average internet traffic will grow by nearly four times (30 percent CAGR) over the same period to reach 1 petabyte by 2022.

      1 A petabyte is equal to 1,000 terabytes or one million gigabytes.

  2. Global internet users will make up 60 percent of the world’s population

    • There will be 4.8 billion internet users by 2022. That’s up from 3.4 billion in 2017 or 45 percent of the world’s population.
  3. Global networked devices and connections will reach 28.5 billion
    • By 2022, there will be 28.5 billion fixed and mobile personal devices and connections, up from 18 billion in 2017—or 3.6 networked devices/connections per person, from 2.4 per person.
    • More than half of all devices and connections will be machine-to-machine by 2022, up from 34 percent in 2017. That’s 14.6 billion connections from smart speakers, fixtures, devices and everything else, up from 6.1 billion.
  4. Global broadband, Wi-Fi and mobile speeds will double or more
    • Average global fixed broadband speeds will nearly double from 39.0 Mbps to 75.4 Mbps.
    • Average global Wi-Fi connection speeds will more than double from 24.4 Mbps to 54.0 Mbps.
    • Average global mobile connection speeds will more than triple from 8.7 Mbps to 28.5 Mbps.
  5. Video, gaming and multimedia will make up more than 85 percent of all traffic
    • IP video traffic will quadruple by 2022. As a result, it will make up an even larger percentage of total IP traffic than before—up to 82 percent from 75 percent.
    • Gaming traffic is expected to grow nine-fold from 2017 to 2022. It will represent four percent of overall IP traffic in 2022.
    • Virtual and augmented reality traffic will skyrocket as more consumers and businesses use the technologies. By 2022, virtual and augmented reality traffic will reach 4.02 exabytes/month, up from 0.33 exabytes/month in 2017.

Regional IP traffic growth details (2017 – 2022)

  • APAC: 173 exabytes/month by 2022, 32 percent CAGR, four-times growth
  • North America: 108 exabytes/month by 2022, 21 percent CAGR, three-times growth
  • Western Europe: 50 exabytes/month 2022, 22 percent CAGR, three-times growth
  • Central & Eastern Europe: 25 exabytes/month by 2022, 26 percent CAGR, three-times growth
  • Middle East and Africa: 21 exabytes/month by 2022, 41 percent CAGR, six-times growth
  • Latin America: 19 exabytes/month by 2022, 21 percent CAGR, three-times growth

Cisco Complete VNI Forecast
The Cisco Complete VNI Forecast includes global, regional, and country-level projections and trends associated with fixed and mobile networks. The full report includes additional information and analysis on IoT by industry vertical, IPv6 adoption, traffic growth by application, traffic patterns, cord cutting implications, Wi-Fi hotspots, broadband network performance and network security issues.

Cisco VNI Methodology
The Cisco VNI Complete Forecast for 2017 to 2022 relies upon independent analyst forecasts and real-world network usage data. Upon this foundation are layered Cisco’s own estimates for global IP traffic and service adoption. A detailed methodology description is included in the complete report. Over its 13-year history, Cisco® VNI research has become a highly regarded measure of the internet’s growth. National governments, network regulators, academic researchers, telecommunications companies, technology experts and industry/business press and analysts rely on the annual study to help plan for the digital future.

Supporting Resources

RSS feed for Cisco: http://newsroom.cisco.com/rss-feeds

About Cisco
Cisco (NASDAQ: CSCO) is the worldwide technology leader that has been making the internet work since 1984. Our people, products, and partners help society securely connect and seize tomorrow’s digital opportunity today. Discover more at newsroom.cisco.com and follow us on Twitter at @Cisco.

Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the U.S. and other countries. A listing of Cisco’s trademarks can be found at www.cisco.com/go/trademarks.

Contact:
Sara Cicero
stutzes@cisco.com

Rapid Micro Biosystems Announces New Vice President of Global Sales

LOWELL, Mass., Nov. 27, 2018 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, a leading provider of automated, non-destructive, rapid microbial detection, is pleased to announce the appointment of Scott White as Vice President of Global Sales. He reports directly to the company’s CEO, Robert Spignesi.

Mr. White has over 20 years of sales experience in the healthcare and technology industries.  Mr. White spent 7 years in progressive roles at Intuitive Surgical (NASDAQ:ISRG), including Area Vice President for the US Southeast / Mid-Atlantic region.  In this role, he led a 120-member sales team across 7 states and 270+ hospitals.  Mr. White grew the region to consecutive #3 and #2 rankings in worldwide sales, and #1 in new technology sales, generating $200 million in revenue.  Mr. White has also served as President of Compass Surgical Partners, a private firm that manages ambulatory surgical centers, Managing Partner of Surgery Center Development Co, a multi-specialty outpatient surgical center business, and in multiple sales roles at C.R. Bard, GlaxoSmithKline and Verizon.

“I am excited to welcome Scott to our executive management team,” said Mr. Spignesi. “He brings extensive experience leading and growing sales organizations and selling market-disruptive technologies.  Scott will be instrumental in leading our growth as we continue to expand the Growth Direct™ system to leading companies globally.”

“I am incredibly honored to be part of Rapid Micro Biosystems and partner with some of the world’s leading healthcare companies,” said Mr. White.  “As we deliver our Growth Direct™ system to the market, our entire team is committed to realizing our mission of being the trusted standard in microbial automation.”

Mr. White holds an MBA in Finance from the University of Miami, and a BS in Business Administration from the University of Florida.

About Rapid Micro Biosystems
Rapid Micro Biosystems delivers the Growth Direct™ System, an automated, non-destructive rapid detection and enumeration technology based on the compendial method for microbial quality control in pharmaceutical manufacturing.  The system automates and accelerates detection and enumeration in the areas of sterility testing, environmental monitoring, and bioburden testing, eliminating manual steps and analysis.  The detection technology, first developed and patented by Dr. Don Straus, Ph.D., uses the natural auto-fluorescence of microbes and requires no reagents. For more information about Rapid Micro Biosystems visit www.rapidmicrobio.com.

Invivoscribe Submits LeukoStrat CDx FLT3 Mutation Assay both in the US and Japan to Support Daiichi Sankyo Submissions for Quizartinib

SAN DIEGO, Nov. 27, 2018 (GLOBE NEWSWIRE) — In support of an ongoing partnership with Daiichi Sankyo, Invivoscribe is pleased to announce submissions of the LeukoStrat® CDx FLT3 Mutation Assay to both the US FDA and the Japan PMDA (Pharmaceuticals and Medical Devices Agency) as the companion diagnostic for quizartinib, which follows Daiichi Sankyo’s respective FDA and PMDA applications for quizartinib in the US and in Japan.

Invivoscribe developed the LeukoStrat CDx FLT3 Mutation Assay in partnership with Daiichi Sankyo as the companion diagnostic that bridges to the global phase 3 QuANTUM-R clinical trial (Europe, United States, Asia excluding Japan) in patients with relapsed/refractory FLT3 ITD AML. Together, the QuANTUM-R clinical trial and open-label phase 2 study of quizartinib (Japan) support the Daiichi Sankyo New Drug Application (NDA) to Japan’s MHLW/PMDA and the FDA in the US for use of quizartinib for treatment of adult patients with relapsed/ refractory FLT3 ITD acute myeloid leukemia (AML).

Timing of this submission reflects the efficiencies of Invivoscribe’s Streamlined CDx program, which integrates a range of CDx activities including development, clinical trials support with rapid patient screening for enrollment, regulatory support and, importantly, commercialization. In addition, they complement Invivoscribe’s prior regulatory approvals of this LeukoStrat CDx FLT3 Mutation Assay as an AML companion diagnostic in support of midostaurin for Novartis (United States and Europe), and gilteritinib fumarate for Astellas (Japan). Astellas and Invivoscribe have also submitted applications for the drug and device to the CDER and CDRH, respectively, in the United States.

This milestone also establishes the LeukoStrat CDx FLT3 Mutation Assay as the international gold standard for comprehensive FLT3 assessment for critically ill acute myeloid leukemia patients as this CDx identifies even the largest ITD mutations, is available worldwide, and generates standardized signal ratios for both ITD and TKD mutations. These criteria are already resulting in more consistent stratification of patients which will help prescribing doctors identify personalized therapy options for their patients and accelerate new drug and therapy approvals by establishing more homogeneous patient populations for clinical trials.

“These LeukoStrat CDx FLT3 Mutation Assay submissions and continuing Daiichi Sankyo partnership represent significant milestones for our company. We welcome opportunities to partner with global pharmaceutical companies interested in developing and commercializing companion diagnostics, whether their therapies are targeting hematologic diseases or solid tumors,” said Jeffrey Miller, Invivoscribe’s CSO and CEO.

About the Invivoscribe LeukoStrat CDx FLT3 Mutation Assay
The LeukoStrat CDx FLT3 Mutation Assay is a PCR-based, in vitro diagnostic test designed to detect internal tandem duplication (ITD) mutations and tyrosine kinase domain (TKD) mutations D835 and I836 in the FLT3 gene in genomic DNA extracted from mononuclear cells obtained from peripheral blood or bone marrow aspirates of patients diagnosed with acute myelogenous leukemia. This globally standardized test includes software that interprets data, generates mutant/wildtype signal ratios for ITD and TKD mutations, and predicts response to both gilteritinib fumarate and midostaurin. This extensively validated assay helps standardize the detection of genetic mutations in the FLT3 gene as one of the most important driver mutations in Acute Myeloid Leukemia (AML). In serving as the companion diagnostic to the Daiichi Sankyo sponsored clinical trials, this test reports out FLT3 ITD mutations alone.

The LeukoStrat test is currently available as a test menu service through the Invivoscribe subsidiaries, LabPMM LLC (San Diego, CA, US), LabPMM GmbH (Martinsried, Germany) and LabPMM GK (Kawasaki City, Japan). LeukoStrat CDx FLT3 Mutation Assay kits are currently distributed in Europe. Distribution of kits in Japan, United States, and China are planned.

About Invivoscribe
Invivoscribe is a privately held biotechnology company dedicated to Improving Lives with Precision Diagnostics. For nearly twenty-five years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality, standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with global pharmaceutical companies interested in developing and commercializing companion diagnostics, and provides expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM), Invivoscribe is an ideal partner from diagnostic development, through clinical trials, regulatory submissions, and commercialization.

For additional information please contact Invivoscribe at support@invivoscribe.com or visit www.invivoscribe.com.